Related Experiment Video
Updated: Aug 8, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
Blood clotting, inflammation, and thrombosis in cardiovascular events: perspectives
Christopher J Boos1, Gergory Y H Lip
1University Department of Medicine, City Hospital, Birmingham B18 7QH, UK.
Insights
Cardiovascular disease (CVD) involves endothelial dysfunction, inflammation, and thrombosis. Novel anticoagulants with anti-inflammatory effects highlight this critical triad in CVD development.
Area of Science:
- Cardiovascular Medicine
- Pathophysiology
- Pharmacology
Background:
- Cardiovascular disease (CVD) is a major global cause of mortality.
- Endothelial dysfunction is a central factor in atherosclerosis development.
- Atherosclerosis is a dynamic process involving endothelial damage, inflammation, thrombosis, and coagulation.
Purpose of the Study:
- To provide an overview of the relationship between inflammation, thrombosis, and coagulation in CVD pathogenesis.
- To discuss novel anticoagulants with anti-inflammatory properties.
Main Methods:
- Review of existing evidence on the interplay of inflammation, thrombosis, and coagulation in CVD.
- Discussion of emerging anticoagulant therapies.
Main Results:
- Inflammation, thrombosis, and coagulation are interconnected and critically influence each other in CVD.
- Novel anticoagulants demonstrate potential by targeting both coagulation and inflammation.
Conclusions:
- The triad of inflammation, thrombosis, and coagulation is fundamental to CVD pathogenesis.
- Targeting this triad with novel therapeutics offers a promising approach for CVD management.
Abstract:
Worldwide, cardiovascular disease (CVD) is a leading cause of death. Endothelial dysfunction is now recognized to be a key platform for the pathophysiological effects of atherosclerosis. It is now well accepted that atherosclerosis is not merely a benign and passive process, but is in fact a dynamic and progressive disease arising from a combination of endothelial damage/dysfunction, inflammation, thrombosis and coagulation leading to potential clot-related vessel occlusion. The between inflammation, thrombosis and coagulation in the pathogenesis of CVD is more than simply association, as it clear that these processes are critically influenced by one another. In this preface we present a basic overview of the evidence in support of this relationship, which will be expanded upon in sequential chapters. In addition we briefly discuss a number of novel anticoagulants which not only reduce coagulation, but have ancillary antiinflammatory properties, thus further supporting the triad of inflammation, thrombosis and coagulation in the development of CVD.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Clot Retraction and Fibrinolysis
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care

